Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hyku Biosciences

Request full access

Precise covalent targeting of disease-causing proteins and developing small molecule therapeutics with novel mechanisms of action to transform conventional treatment paradigms

Burlington, United StatesFounded 2019Biotech & Life Sciences

About Hyku Biosciences

Hyku Biosciences is at the forefront of developing small molecule therapeutics designed to inactivate proteins that drive disease progression. Operating in the biopharmaceutical sector, Hyku focuses on pioneering covalent medicines that target histidine, tyrosine, and lysine binding pockets within disease-causing proteins. This approach offers superior selectivity and drug properties by irreversibly blocking the activity of these targets, expanding beyond the traditional cysteine targeting methods.

The company serves patients suffering from diseases driven by these proteins, aiming to transform conventional treatment paradigms. Hyku's business model revolves around research and development of these novel therapeutics, with revenue generated through partnerships, licensing agreements, and potentially direct sales of approved drugs.

Hyku Biosciences is committed to innovation, collaboration, and respect within its diverse team, all united by the mission to improve patient lives.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
60.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEEDOther financing Sep 2023 $56M $224M KB Investment · RA Capital Management · Droia Oncology Ventures · The Mark Foundation for Cancer Research ↗
SPINOUTOther financing Jan 2019 $0 — University of Virginia —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Hyku Biosciences website traffic

Latest recorded traffic for Hyku Biosciences is 1K monthly website visits, down 33.3% over the last three months. Hyku Biosciences's team declined 25% over the past year.

Latest monthly visits1K 3-month web change-33.3% 1-year team growth-25%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hyku Biosciences in the Burlington ecosystem

Live from Dealroom

The Hyku Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • RA Capital Management
  • Droia Oncology Ventures
  • Novartis Venture Fund
  • KB Investment
  • The Mark Foundation for Cancer Research
  • Eisai Innovation

Other known investors1 additional known investor

  • University of Virginia
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hyku Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hyku Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.